United States Patent 9,511,056: Scope, Claim Architecture, and Patent Landscape
US drug patent 9,511,056 claims a combination regimen for eliminating hepatitis C virus (HCV) in a human patient, using (i) a compound of Formula (the specific chemical identity is not provided in the excerpt) plus (ii) an NS5B polymerase inhibitor, with dependent claims narrowing to nucleotide inhibitors, genotype, and interferon/ribavirin presence or absence.
What does US 9,511,056 claim, in plain scope terms?
Core independent claim (Claim 1)
Claim 1 recites a method of elimination of HCV by administering an effective amount of:
- (1) a compound of Formula (structure not shown in the prompt), and
- (2) an NS5B polymerase inhibitor.
This is a combination-treatment method claim with two elements:
- A defined chemical matter term (the “compound of formula”).
- A functional target term (an NS5B polymerase inhibitor), which can be either nucleotide or non-nucleotide depending on the full specification and claim dependencies.
Claim 2: narrows NS5B inhibitor type
Claim 2 specifies that the NS5B polymerase inhibitor is a:
- nucleotide inhibitor of HCV NS5B polymerase.
This converts Claim 1’s functional category into a more defined mechanistic class (nucleotide NS5B inhibitors).
Claims 3 to 9: treatment context and genotype
Claims 3 to 5 recite interferon and ribavirin status:
- Claim 3: treated without interferon
- Claim 4: treated without ribavirin
- Claim 5: treated with ribavirin
Claims 6 to 9 recite genotype:
- Claim 6: infected with genotype 1
- Claim 7: infected with 1a or 1b
- Claim 8: infected with genotype 1 (mirrors claim 6 under the ribavirin/interferon constraint of the parent chain)
- Claim 9: infected with 1a or 1b (mirrors claim 7 under the parent chain)
Net effect: the independent claim is broad on NS5B inhibitor type and combination formulation, then dependent claims narrow on:
- nucleotide NS5B inhibitors (Claim 2),
- no interferon (Claim 3),
- ribavirin on/off (Claims 4 and 5),
- genotype 1 (Claims 6-9).
How broad is “eliminating hepatitis C virus” as a method endpoint?
Claim language uses “eliminating hepatitis C virus in a human patient.” In practice, this type of phrasing is typically prosecuted to cover outcomes such as sustained virologic response or viral clearance, depending on the patent specification’s definitions. From a landscape perspective, this endpoint language matters because it:
- ties the method to a virologic success criterion (not merely dosing),
- can support enforceability against regimens that achieve viral clearance even if measured over defined windows (as defined in the specification).
Because the prompt does not include the specification definitions, this endpoint should be treated as an outcome requirement that can be satisfied by standard HCV efficacy markers used in clinical trials and label endpoints.
What is the claim “wiring” for scope and design-around risk?
Key claim elements
- Element A (chemical): “a compound of formula” (exact identity missing in the excerpt).
- Element B (mechanism class): “NS5B polymerase inhibitor,” narrowed to nucleotide NS5B inhibitor in Claim 2.
- Element C (population): “a human patient in need thereof.”
- Element D (regimen components): includes compound A and NS5B inhibitor B; ribavirin and interferon are present/absent depending on dependent claims.
- Element E (genotype): genotype 1, with sub-typing 1a/1b in dependent claims.
Scope implications
- Combination requirement is strict. To infringe any claim in this chain, an accused regimen generally needs both the “compound of formula” and an NS5B polymerase inhibitor (or the nucleotide NS5B inhibitor class for Claim 2 and downstream).
- NS5B inhibitors are the swap surface. Claim 1 broadly covers NS5B polymerase inhibitors; Claim 2 restricts to nucleotide inhibitors. Competitors can reduce risk by avoiding:
- nucleotide NS5B inhibitors when targeting Claim 2 and its descendants,
- pairing their regimen with the specific “compound of formula” covered by this patent.
- Interferon absence narrows, not broadens. Claim 3 recites “without interferon.” If an accused regimen uses interferon, Claim 3 and its dependent claims would likely not read, but Claim 1 could still capture regimens if the dependent narrowing is not required for independent claim coverage.
- Ribavirin on/off is explicitly claimed. Claims 4 and 5 carve out both scenarios under the interferon-absent chain. That blocks a common design-around strategy of “switching ribavirin status.”
Claim chart logic by dependence (based only on provided text)
| Claim |
Relationship |
Treatment constraints included in that claim |
| 1 |
Independent |
Effective amount of (compound of formula) + (NS5B polymerase inhibitor); “eliminating HCV” endpoint |
| 2 |
Depends on 1 |
NS5B inhibitor is a nucleotide inhibitor |
| 3 |
Depends on 2 |
Treated without interferon |
| 4 |
Depends on 3 |
Treated without ribavirin |
| 5 |
Depends on 3 |
Treated with ribavirin |
| 6 |
Depends on 3 |
HCV genotype 1 |
| 7 |
Depends on 3 |
HCV genotype 1a or 1b |
| 8 |
Depends on 4 |
HCV genotype 1 |
| 9 |
Depends on 4 |
HCV genotype 1a or 1b |
What does this imply for the patent landscape (strategic intersections)?
Landscape axis 1: NS5B nucleotide inhibitors
US HCV regimens historically use NS5B polymerase inhibitors in two major classes:
- nucleotide inhibitors (nucleos(t)ide analogs),
- non-nucleotide inhibitors (allosteric).
Because Claim 2 locks to nucleotide inhibitors, infringement risk is highest where the accused regimen includes an NS5B nucleoside/nucleotide inhibitor alongside the covered “compound of formula.”
Landscape axis 2: interferon-free, ribavirin-flexible regimens
Claims explicitly include interferon-free regimens and both ribavirin-off and ribavirin-on embodiments. This matches the evolution of HCV therapy toward direct-acting antiviral (DAA) combinations where interferon use is eliminated and ribavirin use is variable.
From an infringement risk standpoint:
- A regimen that includes interferon may avoid some dependent claims but does not automatically avoid Claim 1.
- A regimen that toggles ribavirin status does not evade Claims 4 and 5 because both are claimed.
Landscape axis 3: genotype 1 focus
Dependent claims center genotype 1 and its subtypes 1a/1b. Genotype restrictions reduce breadth relative to pan-genotype claims, but they still carve out the dominant commercial segment for historical DAA development.
Landscape axis 4: “compound of formula” as the gating element
The “compound of formula” is the strongest determinant of landscape position, because it is likely the specific proprietary chemical matter (or a constrained class defined by the formula). In practice, the competitive set depends on whether the covered compound maps to:
- a specific protease inhibitor,
- an NS5A inhibitor,
- or a separate component outside the NS5B category.
The provided excerpt does not include the formula identity, so mapping cannot be completed here.
Scope boundaries: what is not claimed based on the provided excerpt?
From the claim text you provided, the following are not evidenced:
- No explicit inclusion of other direct-acting antiviral targets (protease, NS5A) by name in the excerpt.
- No explicit coverage of genotypes other than 1 and 1a/1b in the dependent claims you provided.
- No explicit dosing schedule, duration, or virologic measurement window.
- No explicit therapy setting beyond “a human patient in need thereof.”
Operational implications for design and diligence
High-risk regimen profiles
The patent has the highest infringement exposure where an accused therapy:
- includes the specific “compound of formula” (chemical gate),
- uses an NS5B polymerase inhibitor (functional gate),
- is interferon-free (for dependent claims in the chain),
- uses nucleotide NS5B inhibition (for Claim 2 and downstream),
- covers genotype 1 and potentially 1a/1b (for genotype-dependent claims),
- uses either ribavirin or no ribavirin (both are claimed under the interferon-free chain).
Primary design-around lever
Because ribavirin/interferon status is captured in dependent claims, the principal design-around lever is usually:
- replacing the “compound of formula” with a non-covered chemical entity, or
- avoiding NS5B polymerase inhibitors, or
- using a different NS5B inhibitor class that does not satisfy the “nucleotide NS5B polymerase inhibitor” limitation when targeting Claim 2 descendants.
Key Takeaways
- US 9,511,056 claims an HCV elimination method using a two-component combination: a compound of formula plus an NS5B polymerase inhibitor.
- Claim 2 narrows NS5B inhibitors to nucleotide inhibitors.
- Dependent claims require interferon-free treatment, explicitly cover ribavirin on/off, and focus on HCV genotype 1 and 1a/1b.
- For enforcement and freedom-to-operate, the decisive variable is whether the accused regimen includes the specific “compound of formula” and a nucleotide NS5B inhibitor; ribavirin status alone is not a reliable escape route.
FAQs
1) Does Claim 1 require interferon or ribavirin?
No. Claim 1 only requires the compound of formula plus an NS5B polymerase inhibitor to eliminate HCV. Interferon/ribavirin limitations appear in dependent claims (Claims 3-5) in the excerpt.
2) Is the NS5B inhibitor type limited in the broadest claim?
No. Claim 1 includes “an NS5B polymerase inhibitor” broadly. The nucleotide limitation appears in Claim 2.
3) If a regimen uses interferon, does it avoid infringement?
It avoids the specific dependent limitations in claims that explicitly require “without interferon,” but it does not automatically avoid Claim 1, which does not impose an interferon requirement in the excerpt.
4) Does adding or removing ribavirin change risk?
Under the interferon-free chain, the patent has claims for both “without ribavirin” (Claim 4) and “with ribavirin” (Claim 5), so ribavirin status alone does not remove coverage.
5) Is genotype coverage restricted to HCV genotype 1?
The genotype-dependent claims in your excerpt are limited to genotype 1 and 1a/1b. The independent claim text you provided does not explicitly restrict genotype.
References
[1] United States Patent US 9,511,056 (claims as provided in prompt excerpt).
